LLY vs NFLX: Which Is the Better Buy?
Side-by-side comparison of Eli Lilly and Company and Netflix, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-04.
Eli Lilly and Company · Healthcare
$934.34
+98.6% upside to fair value
Grade B
High Quality
VS
Netflix, Inc. · Communication Services
$91.02
+95.7% upside to fair value
Grade B
High Quality
QuantHub Verdict
LLY has more upside to fair value
(+98.6%).
NFLX trades at a lower forward P/E
(28.7x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
LLY |
NFLX |
| Current Price |
$934.34 |
$91.02 |
| Fair Value Estimate |
$1,855.91 |
$178.10 |
| Upside to Fair Value |
+98.6%
|
+95.7%
|
| Market Cap |
$882.8B |
$383.3B |
| Forward P/E |
33.1x
|
28.7x
|
| EV / EBITDA |
27.9x
|
11.4x
|
| Price / Sales |
12.2x
|
8.2x
|
| Price / FCF |
65.0x
|
32.2x
|
| Revenue Growth YoY |
+55.5%
|
+16.2%
|
| Gross Margin |
82.7%
|
49.0%
|
| Operating Margin |
46.3%
|
29.7%
|
| Return on Equity |
101.3%
|
49.2%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
1.54%
|
3.1%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
Eli Lilly and Company is a leading global pharmaceutical firm with a dominant position in the diabetes and obesity markets, driven by its blockbuster GLP-1 drugs Mounjaro and Zepbound which generated $36.5 billion in FY2025. The company reported $65.2 billion in total revenue for 2025, making it the top pharma by revenue globally. It exhibits high business quality with a durable competitive moat …
Netflix, Inc. operates a leading global streaming entertainment service with a dominant streaming segment accounting for nearly 100% of its revenue. The company benefits from a high-quality business model characterized by strong revenue growth of 16.2% and earnings growth of 82.8% in the most recent quarter, a robust 49.2% return on equity, and healthy margins with a 29.7% operating margin and 28…
Accumulation Zones
| Metric |
LLY |
NFLX |
| Zone Low |
$1,391.93 |
$133.57 |
| Zone High |
$1,577.52 |
$151.38 |
| In Buy Zone? |
Yes
|
Yes
|